Avidity Competitors

Delisted . USA . 
Stock . Avidity Biosciences
RNADelisted Stock  USD 72.80  0.05  0.07%   
Avidity Biosciences competes with Jazz Pharmaceuticals, Madrigal Pharmaceuticals, Caris Life, Moderna, and Abivax SA; as well as few others. The company runs under Biotechnology sector within Health Care industry. Analyzing Avidity Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Avidity Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Avidity Biosciences Correlation with its peers.

Avidity Biosciences vs Rhythm Pharmaceuticals Correlation

Very good diversification

The correlation between Avidity Biosciences and RYTM is -0.44 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Avidity Biosciences and RYTM in the same portfolio, assuming nothing else is changed.

Moving together with Avidity Stock

  0.79GXEA Galapagos NVPairCorr
  0.698VP1 AVRICORE HEALTH INCPairCorr
  0.73EQ EquilliumPairCorr

Moving against Avidity Stock

  0.84VCYT VeracytePairCorr
  0.76OSE OSE Pharma SAPairCorr
  0.63RAC Race OncologyPairCorr
  0.45VCEL Vericel Corp Ord Downward RallyPairCorr
  0.34DMAC DiaMedica TherapeuticsPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
72.6472.8072.96
Details
Intrinsic
Valuation
LowRealHigh
61.4261.5880.08
Details
Naive
Forecast
LowNextHigh
72.4572.6172.77
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
72.8072.8072.80
Details

Avidity Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Avidity Biosciences and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Avidity and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Avidity Biosciences does not affect the price movement of the other competitor.

High positive correlations

CAI
+ 0.81
MDGL
RYTM
+ 0.57
MDGL
RYTM
+ 0.55
CAI
TECH
+ 0.33
NUVL
NUVL
+ 0.28
CYTK
RYTM
+ 0.28
NUVL
  

High negative correlations

MRNA
- 0.88
MDGL
MRNA
- 0.66
CAI
RYTM
- 0.45
MRNA
TECH
- 0.39
ABVX
CYTK
- 0.37
CAI
CAI
- 0.36
JAZZ

Risk-Adjusted Indicators

There is a big difference between Avidity Stock performing well and Avidity Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Avidity Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Avidity Biosciences Competitive Analysis

The better you understand Avidity Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Avidity Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Avidity Biosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
RNA JAZZ MDGL CAI MRNA ABVX CYTK NUVL TECH RYTM
 0.07 
 72.80 
Avidity
 0.03 
 189.97 
Jazz
 3.11 
 432.00 
Madrigal
 4.68 
 20.14 
Caris
 3.60 
 53.57 
Moderna
 1.52 
 121.28 
Abivax
 0.65 
 62.22 
Cytokinetics
 1.91 
 101.95 
Nuvalent
 1.86 
 59.00 
Bio
 5.45 
 92.73 
Rhythm
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Not too volatile
Not too volatile
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Solid
Mild
Weakest
Weakest
Solid
Weak
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Low
Low
Small
Low
Low
Small
Low
Low
Small
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Not Available
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Cautious Hold
Cautious Hold
Cautious Hold
Buy
Strong Sell
Hold
Cautious Hold
Hold
Sell
Current Ratio
12.0
3.16
2.55
0.45
2.1
N/A
9.01
25.79
3.44
5.59
Net Asset
1.96 B
11.66 B
1.26 B
1.13 B
12.34 B
205.23 M
1.42 B
1.41 B
2.56 B
480.2 M
Profit Margin
N/A
-0.0835
-0.3
-0.0839
-1.45
N/A
N/A
N/A
0.0667
-1.04
EBITDA
(680.48 M)
108.46 M
(264.47 M)
11.38 M
(2.55 B)
(171.88 M)
(775.27 M)
(10.48 M)
216.88 M
(174.12 M)
Operating Margin
-295.9
0.25
-0.19
0.3
-1.26
-44.41
-10.05
N/A
0.2
-0.82
Current Valuation
5.27 B
14.68 B
9.06 B
5.35 B
16.4 B
8.93 B
7.84 B
6.97 B
9.41 B
5.93 B
Price To Book
5.4
2.71
16.3
11.88
2.42
15.87
60.31
9.36
4.59
41.62
Retained Earnings
(1.58 B)
646.18 M
(2.09 B)
(2.55 B)
7.22 B
(438.88 M)
(3.49 B)
(972.43 M)
1.07 B
(1.35 B)
Current Asset
50.65 M
1.26 B
363.58 K
131.15 M
850 K
N/A
113.11 M
N/A
253.89 M
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.56
N/A
Beta
0.93
0.25
-1.02
1.47
1.34
-0.11
0.55
1.32
1.47
2.04
Number Of Employees
511
2.89 K
915
1.77 K
4.7 K
67
498
218
3.1 K
283
Shares Outstanding
154.48 M
61.56 M
22.71 M
282.15 M
390.73 M
77.83 M
122.26 M
67.27 M
156.45 M
66.74 M
Cash Flow From Operations
(650.44 M)
1.36 B
(189.55 M)
83.16 M
(1.87 B)
(154.07 M)
(510.01 M)
(275.21 M)
287.56 M
(115.67 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0054
N/A
Total Debt
94.56 M
1.08 B
354.36 M
169 K
1.92 B
97.36 M
1.28 B
164.37 M
444.06 M
3.99 M
Return On Equity
-0.44
-0.0847
-0.42
-0.45
-0.29
-5.0
-5.72
-0.37
0.0397
-0.9
Return On Asset
-0.26
0.0522
-0.16
0.0384
-0.15
-0.58
-0.27
-0.2
0.0652
-0.28
Number Of Shares Shorted
8.75 M
6.04 M
3.62 M
6.08 M
71.34 M
3.17 M
14.78 M
5.68 M
11.31 M
6.02 M
Book Value Per Share
11.17
70.3
26.39
2.04
21.95
-0.76
-5.49
15.96
12.9
2.07
Current Liabilities
16.97 M
226.64 M
49.28 M
215.06 M
2.44 M
N/A
31.65 M
5.46 M
54.15 M
N/A
Total Asset
1.96 B
11.66 B
1.26 B
1.13 B
12.34 B
205.23 M
1.42 B
1.41 B
2.56 B
480.2 M
Debt To Equity
0.031
2.12
0.6
2.41
0.07
N/A
2.93
2.81
0.19
0.011
Short Ratio
5.36
6.97
11.15
2.54
5.05
1.56
9.01
11.34
4.18
9.44
Target Price
74.64
222.63
667.57
33.6
42.25
123.78
91.17
143.53
75.25
140.67
Last Dividend Paid
N/A
N/A
N/A
1.2
N/A
N/A
N/A
N/A
0.32
N/A
Shares Owned By Institutions
92.38
96.92
92.15
59.34
77.47
49.0
99.22
97.09
99.32
99.18
Market Capitalization
11.24 B
11.7 B
9.81 B
5.68 B
20.93 B
8.19 B
7.61 B
7.41 B
9.23 B
6.19 B
Price To Earning
-12.91
35.18
-13.96
17.74
6.37
N/A
-37.76
-0.06
74.38
N/A
Price To Earnings To Growth
N/A
0.62
N/A
0.9
N/A
N/A
-0.42
N/A
0.81
0.75
Price To Sales
599.22
2.74
10.24
7.0
10.77
1805.67
86.41
N/A
7.59
32.61
Net Income
(684.63 M)
(356.15 M)
(288.28 M)
(68.09 M)
(2.82 B)
(176.24 M)
(784.96 M)
(425.38 M)
73.4 M
(196.54 M)
Earnings Per Share
-4.19
-5.83
-12.85
-3.52
-7.26
-3.58
-6.3
-5.33
0.53
-3.1
Shares Owned By Insiders
3.84
3.08
7.85
48.46
7.39
N/A
0.78
2.91
0.68
0.82
Revenue
18.75 M
4.27 B
958.4 M
812.03 M
1.94 B
10.79 M
88.04 M
N/A
1.22 B
189.76 M
Working Capital
1.44 B
1.92 B
863.65 M
50.31 M
5.89 B
77.84 M
928.27 M
1.08 B
432.45 M
258.68 M
Cash And Equivalents
398.22 M
899.36 M
211.77 M
38.81 M
8.35 B
N/A
586.03 M
256.96 M
247.03 M
235.6 M
Cash Per Share
7.64
14.28
12.38
2.26
21.73
N/A
6.22
5.31
6.3
4.64
Gross Profit
(540.4 M)
3.91 B
902.25 M
539.17 M
(2.06 B)
6.02 M
(327.99 M)
N/A
809.63 M
170.26 M
Day Typical Price
72.79
190.17
434.84
20.41
52.64
121.09
62.32
101.94
58.08
93.7
Accumulation Distribution
0.003
0.0252
0.0282
0.0866
0.0539
0.0244
0.0148
0.0326
0.0486
0.0687
Market Facilitation Index
0.22
4.85
12.49
1.86
2.89
2.99
0.93
3.38
2.87
6.7
Daily Balance Of Power
0.2273
(0.01)
(1.11)
0.4839
0.6436
0.6054
(0.44)
(0.59)
0.3763
(0.80)
Period Momentum Indicator
0.05
(0.05)
(13.85)
0.9
1.86
1.81
(0.41)
(1.98)
1.08
(5.34)
Rate Of Daily Change
1.0
1.0
0.97
1.05
1.04
1.02
0.99
0.98
1.02
0.95
Day Median Price
72.79
190.27
436.26
20.54
52.18
121.0
62.38
101.94
57.63
94.19
Price Action Indicator
0.035
(0.33)
(11.18)
0.05
2.33
1.19
(0.36)
(0.98)
1.91
(4.13)
Relative Strength Index
50.59
12.95
46.25
88.41
16.21
4.55
85.67
7.2
10.93
29.18
Coefficient Of Variation
525.26
1747.45
(884.55)
(1,539)
344.32
3763.34
(7,073)
(10,436)
(7,147)
(3,669)
Mean Deviation
0.1444
1.35
1.86
2.45
3.22
2.91
2.17
1.89
1.83
2.47
Jensen Alpha
0.0338
0.0903
(0.41)
(0.31)
1.23
0.0802
(0.1)
(0.06)
(0.17)
(0.20)
Total Risk Alpha
0.0083
(0.12)
(0.63)
(0.57)
0.8507
(0.34)
(0.34)
(0.30)
(0.29)
(0.44)
Sortino Ratio
(0.25)
0.0209
N/A
N/A
0.3142
0.0062
N/A
N/A
N/A
N/A
Downside Variance
0.0405
4.56
N/A
N/A
15.92
13.92
N/A
N/A
N/A
N/A
Standard Deviation
0.2128
2.35
2.83
3.32
4.63
4.25
2.74
2.58
2.39
3.26
Kurtosis
4.07
14.7
4.37
1.37
2.3
7.47
1.64
2.83
0.4842
1.93
Potential Upside
0.3504
1.85
3.9
4.4
9.21
6.2
3.98
2.94
3.72
4.76
Treynor Ratio
(0.75)
0.2909
(0.34)
(0.21)
1.04
0.3629
(0.08)
(0.12)
(0.03)
(0.07)
Maximum Drawdown
1.42
17.22
19.67
17.67
23.11
29.38
15.74
15.7
12.41
18.69
Variance
0.0453
5.53
8.0
11.01
21.41
18.05
7.53
6.67
5.73
10.61
Market Risk Adjusted Performance
(0.74)
0.3009
(0.33)
(0.20)
1.05
0.3729
(0.07)
(0.11)
(0.02)
(0.06)
Risk Adjusted Performance
0.1198
0.0505
(0.08)
(0.04)
0.2307
0.0285
(0)
(0.0003)
(0)
(0.01)
Skewness
0.6602
2.35
(0.26)
(0.77)
0.8977
1.55
(0.67)
0.6781
0.2577
0.74
Semi Deviation
0.0
1.92
N/A
N/A
2.95
3.6
N/A
N/A
N/A
N/A
Information Ratio
(0.23)
0.019
(0.14)
(0.09)
0.271
0.0054
(0.05)
(0.04)
(0.05)
(0.05)
Value At Risk
(0.29)
(3.95)
(3.53)
(6.33)
(5.95)
(6.09)
(3.85)
(3.90)
(3.92)
(5.07)
Expected Short fall
(0.18)
(1.30)
N/A
N/A
(3.65)
(3.02)
N/A
N/A
N/A
N/A
Downside Deviation
0.2013
2.14
N/A
N/A
3.99
3.73
N/A
N/A
N/A
N/A
Semi Variance
(0.01)
3.69
N/A
N/A
8.69
12.96
N/A
N/A
N/A
N/A

Avidity Biosciences Competition Performance Charts

Five steps to successful analysis of Avidity Biosciences Competition

Avidity Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Avidity Biosciences in relation to its competition. Avidity Biosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Avidity Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Avidity Biosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Avidity Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Avidity Biosciences position

In addition to having Avidity Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Compulsion Thematic Idea Now

Compulsion
Compulsion Theme
Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. The Compulsion theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Compulsion Theme or any other thematic opportunities.
View All  Next Launch
Check out Avidity Biosciences Correlation with its peers.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Consideration for investing in Avidity Stock

If you are still planning to invest in Avidity Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Avidity Biosciences' history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Commodity Directory
Find actively traded commodities issued by global exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY